glp-1 novo Nordisk Finds Medicare Patients Prefer Pill Over Shot for Weight Loss Novo Nordisk's oral GLP-1 drug

Our leading data and analytics capabilities enable scenariobased modeling to help plan sponsors anticipate cost impacts and make datadriven decisions

The Asia-Pacific region is the fastest-growing oral GLP-1 market due to the rapidly increasing prevalence of diabetes and obesity, particularly in China, India, and Japan

The physiological roles of secretin and its receptor

Endothelial GLP-1 (Glucagon-Like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension

Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al